Gaps in Prenatal Hepatitis B Screening and Management of HBsAg Positive Pregnant Persons in the U.S., 2015-2020.

Autor: Pham TTH; Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Palo Alto, California., Maria N; Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Palo Alto, California., Cheng V; Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Palo Alto, California., Nguyen B; Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Palo Alto, California., Toy M; Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Palo Alto, California., Hutton D; Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, Michigan., Conners EE; Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia., Nelson NP; Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia., Salomon JA; Center for Health Policy/Center for Primary Care and Outcomes Research, Stanford University, Stanford, California., So S; Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Palo Alto, California. Electronic address: samso@stanford.edu.
Jazyk: angličtina
Zdroj: American journal of preventive medicine [Am J Prev Med] 2023 Jul; Vol. 65 (1), pp. 52-59. Date of Electronic Publication: 2023 Mar 10.
DOI: 10.1016/j.amepre.2023.01.041
Abstrakt: Background: The Advisory Committee for Immunization Practices (ACIP) recommends testing all pregnant women for hepatitis B surface antigen (HBsAg) and testing HBsAg-positive pregnant women for hepatitis B virus deoxyribonucleic acid (HBV DNA). HBsAg-positive pregnant persons are recommended by the American Association for the Study of Liver Diseases to receive regular monitoring, including alanine transaminase (ALT) and HBV DNA and antiviral therapy for active hepatitis and to prevent perinatal HBV transmission if HBV DNA level is >200,000 IU/mL.
Methods: Using Optum Clinformatics Data Mart Database claims data, pregnant women who received HBsAg testing and HBsAg-positive pregnant persons who received HBV DNA and alt testing and antiviral therapy during pregnancy and after delivery during January 1, 2015-December 31, 2020 were analyzed.
Results: Among 506,794 pregnancies, 14.6% did not receive HBsAg testing. Pregnant women more likely to receive testing for HBsAg (p<0.01) were persons aged ≥20 years, were Asian, had >1 child, or received education beyond high school. Among the 0.28% (1,437) pregnant women who tested positive for hepatitis B surface antigen, 46% were Asian. The proportion of HBsAg-positive pregnant women who received HBV DNA testing during pregnancy and in the 12 months after delivery was 44.3% and 28.6%, respectively; the proportion that received hepatitis B e antigen was 31.6% and 12.7%, respectively; the proportion that received ALT testing was 67.4% and 47%, respectively; and the proportion that received HBV antiviral therapy was 7% and 6.2%, respectively.
Conclusions: This study suggests that as many as half a million (∼14%) pregnant persons who gave birth each year were not tested for HBsAg to prevent perinatal transmission. More than 50% of HBsAg-positive persons did not receive the recommended HBV-directed monitoring tests during pregnancy and after delivery.
(Copyright © 2023 American Journal of Preventive Medicine. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: